# Tecentriq® (atezolizumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/atezolizumab

> The FDA approved Tecentriq® (atezolizumab), sponsored by NovoCure Ltd (NVCR), on Oct 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Tecentriq® (atezolizumab) |
| Codes |  |
| Sponsor | NovoCure Ltd (NVCR) https://sec-api.dev/companies/nvcr/catalysts |
| Indications | [Metastatic Pancreatic Ductal Adenocarcinoma](https://sec-api.dev/indications/metastatic-pancreatic-ductal-adenocarcinoma) |
| Modality | antibody |
| FDA designations | fast track, priority review |

## Timeline

### Jan 2024: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2024-11-13, last confirmed 2024-11-13.
- SEC Form 10-Q (accession 0001437749-24-034697): "In January 2024, the Company opened the Phase 1 portion of the Acclaim-3 study for enrollment and enrolled and dosed the first patient in May 2024." https://www.sec.gov/Archives/edgar/data/1595248/000143774924034697/gnpx20240930_10q.htm
- SEC Form 10-Q (accession 0001437749-24-034697): "In January 2024, we opened the Phase 1 portion of the Acclaim-3 study for enrollment and enrolled and dosed the first patient in May 2024." https://www.sec.gov/Archives/edgar/data/1595248/000143774924034697/gnpx20240930_10q.htm

### Oct 2024: topline data readout

- Status: completed, met. Date confidence: month. Stage: 3.
- First seen 2025-11-05, last confirmed 2026-11-02.
- SEC Form 10-Q (accession 0001232524-26-000057): "In October 2024, we announced positive top-line results from the Phase 3 IMforte trial showing a statistically significant and clinically meaningful progression-free survival and overall survival benefit." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000057/jazz-20260930.htm
- SEC Form 10-Q (accession 0001232524-25-000074): "In October 2024, we announced positive top-line results from the trial showing a statistically significant and clinically meaningful" https://www.sec.gov/Archives/edgar/data/1232524/000123252425000074/jazz-20250930.htm

### 1H 2025: NDA/BLA submission

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-02-25, last confirmed 2025-02-25.
- Press release filed with the SEC (EX-99) (accession 0001232524-25-000009): "•On track to submit an sNDA in 1H25 for Zepzelca in combination with Tecentriq® (atezolizumab) as maintenance therapy in 1L ES-SCLC based on the potentially practice-changing results from the Phase 3 IMforte trial." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000009/a4q24financialpr.htm
- Press release filed with the SEC (EX-99) (accession 0001232524-25-000009): "•Based on potentially practice-changing positive results from the Phase 3 IMforte trial, the Company plans to submit a supplemental New Drug Application (sNDA) for Zepzelca's use in combination with Tecentriq as maintenance therapy in first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC) in 1H25." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000009/a4q24financialpr.htm

### Jun 2025: label expansion decision

- Status: completed, approved. Date confidence: month.
- First seen 2025-11-05, last confirmed 2026-05-05.
- SEC Form 10-Q (accession 0001232524-26-000025): "In June 2025, FDA granted priority review of the sNDA and we subsequently received FDA approval in October 2025 for the combination as a first-line maintenance treatment of adult patients with extensive-stage SCLC whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000025/jazz-20260331.htm
- SEC Form 10-K (accession 0001232524-26-000013): "In June 2025, FDA granted priority review of the sNDA and we subsequently received FDA approval in October 2025 for the combination as a first-line maintenance treatment of adult patients with extensive-stage SCLC whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000013/jazz-20251231.htm
- SEC Form 10-Q (accession 0001232524-25-000074): "In June 2025, the FDA granted Priority Review of the sNDA and we subsequently received FDA approval in October 2025 for the combination as a maintenance treatment of adult patients with extensive-stage SCLC whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000074/jazz-20250930.htm

### 2H 2025: interim data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2025-01-13, last confirmed 2025-01-23.
- SEC Form 8-K (accession 0001437749-25-000932): "The Company expects to complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the study in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1595248/000143774925000932/gnpx20250105_8k.htm
- SEC Form 8-K (accession 0001437749-25-001630): "The Company expects to complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the study in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1595248/000143774925001630/gnpx20241220_8k.htm

### Oct 2025: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2026-08-03, last confirmed 2026-08-03.
- SEC Form 10-Q (accession 0001232524-26-000045): "In October 2025, we received FDA approval for the combination as a maintenance treatment of adult patients with extensive-stage SCLC whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm

### October 7, 2025: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2025-08-05, last confirmed 2025-08-06.
- Press release filed with the SEC (EX-99) (accession 0001232524-25-000061): "•Zepzelca and atezolizumab (Tecentriq®) combination granted U.S. FDA Priority Review for 1L maintenance treatment of ES-SCLC based on positive data from IMforte trial; PDUFA action date of October 7, 2025." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000061/a2q25financialpr.htm
- Press release filed with the SEC (EX-99) (accession 0001232524-25-000061): "•Zepzelca and atezolizumab were granted U.S. FDA Priority Review for 1L extensive-stage (ES) SCLC in the maintenance setting with a Prescription Drug User Fee Act (PDUFA) action date of October 7, 2025." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000061/a2q25financialpr.htm
- SEC Form 10-Q (accession 0001232524-25-000063): "In June 2025, we announced the FDA granted Priority Review of the sNDA to support this combination in the first-line maintenance setting with a PDUFA action date of October 7, 2025." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000063/jazz-20250630.htm

### November 18, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Metastatic Pancreatic Ductal Adenocarcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06390059 (EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-18 (ACTUAL); Lead Sponsor NovoCure Ltd.." https://clinicaltrials.gov/study/NCT06390059

### Q1 2026: interim data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-09-16, last confirmed 2025-11-12.
- Press release filed with the SEC (EX-99) (accession 0001129928-25-000077): "The Company anticipates providing a Cohort 5 interim efficacy update, including overall survival, in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1129928/000112992825000077/gobletupdate.htm
- Press release filed with the SEC (EX-99) (accession 0001129928-25-000089): "We expect to provide a Cohort 5 interim efficacy update, including overall survival, in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1129928/000112992825000089/ex992-q32025mda.htm

### 1H 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2026-02-26, last confirmed 2026-02-26.
- Press release filed with the SEC (EX-99) (accession 0001704292-26-000014): "Zai Lab also plans to initiate a Phase 1 study to explore zoci in a novel combination in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1704292/000170429226000014/zlab-20260226x8kex991.htm

### 1H 2026: interim data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-02-10, last confirmed 2026-02-23.
- SEC Form 8-K (accession 0001437749-26-004954): "The Company expects to complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the study in the first half of 2026 and expects the interim analysis in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1595248/000143774926004954/gnpx20260220_8k.htm
- SEC Form 8-K (accession 0001437749-26-003577): "The Company expects to complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the study in the first half of 2026 and expects the interim analysis in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1595248/000143774926003577/gnpx20260209_8k.htm

### September 30, 2026: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-02, last confirmed 2026-11-02.
- Press release filed with the SEC (EX-99) (accession 0001232524-26-000056): "•On September 30, 2026, the FDA approved the label supplement removing the second-line indication." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000056/a3q26earningsrelease.htm

### Oct 2026: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2026-11-05, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001159036-26-000143): "•In October 2026, Roche announced the FDA has approved TECENTRIQ® (atezolizumab) and TECENTRIQ HYBREZA® (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair ("dMMR") colon cancer, a type of tumour characterized by high mutation rates." https://www.sec.gov/Archives/edgar/data/1159036/000115903626000143/ex991q320268-k.htm

### 1H 2027: NDA/BLA submission

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-08-06, last confirmed 2026-08-06.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-053791): "•Second-Line Plus ES-SCLC: Complete enrollment in the global pivotal Phase 3 DLLEVATE study in the first half of 2027 followed by a planned interim analysis with the potential to support a BLA submission for accelerated approval." https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm

### 1H 2027: interim data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-08-06, last confirmed 2026-08-06.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-053791): "•Second-Line Plus ES-SCLC: Complete enrollment in the global pivotal Phase 3 DLLEVATE study in the first half of 2027 followed by a planned interim analysis with the potential to support a BLA submission for accelerated approval." https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm

## Same indication

- [Botvymo® (botensilimab)](https://sec-api.dev/pdufa/botensilimab) (AGEN)

Calendar months: [October 2025](https://sec-api.dev/fda-calendar/2025-10)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/atezolizumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Tecentriq® (atezolizumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/atezolizumab

```bibtex
@misc{secapidev_pdufa_atezolizumab_20261116,
  title        = {Tecentriq® (atezolizumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/atezolizumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_atezolizumab_20261116","title":"Tecentriq® (atezolizumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/atezolizumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
